Share

New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meeting

New pooled data from the Phase 2 and Phase 3 clinical trials of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc, will be presented during an oral plenary presentation at the 89th Annual Meeting of the American Thyroid Association (ATA) in Chicago on Oct. 31. The U.S. Food and Drug Administration is currently evaluating...
Share

Researchers Identify Role of ATP-Binding Cassette Transporters in Anaplastic Thyroid Cancer Resistance to Chemotherapy

ATP-binding cassette (ABC) transporters are the major determinants of anaplastic thyroid cancer (ATC) resistance to chemotherapy, and these transporters could be key in tailoring treatments for patients with ATC, according to a paper recently published in Endocrinology. Researchers led by Vahid Haghpanah, MD, MPH, PhD, of the Endocrinology and Metabolism Research at the Tehran University...
Share

Takeda Announces NATPARA Special Use Program in the U.S.

In the wake of the recall of hypoparathyroidism drug NATPARA, the drug’s manufacturer, Takeda, is working with the FDA to develop a Special Use Program. The program is intended to support patients previously prescribed NATPARA who are facing life-threatening complications as a result of discontinuation of NATPARA. Through this program, healthcare providers will be able...
Share

Endocrine Society, ASBMR Issue Joint Statement on Natpara Recall

In response to the recent recall of Natpara for the treatment of hypoparathyroidism, the Endocrine Society and the American Society for Bone Mineral Research (ASBMR) have drafted the following guidance for clinicians. The recall of NATPARA®, recombinant human PTH(1-84), in the United States has caused significant concerns and uncertainties for patients with hypoparathyroidism who are...
Share

CEU PREVIEW: Graves’ Anatomy: Transatlantic Differences in Treating Graves’ Hyperthyroidism

EN0719-CEU_cover-small Disagreements abound in treating Graves’ hyperthyroidism from the U.S. to Europe as different treatment protocols take precedence. In both Seattle and Miami, “Diagnosis and Management of Graves’ Hyperthyroidism” will demonstrate these conflicting practices and the progress that has been achieved. Graves’ disease – the most common cause of hyperthyroidism – affects between 1% and 1.5%...
Share

Rise of the Machines: Artificial Intelligence in Healthcare

Artificial intelligence – once only found in a Steven Spielberg movie – is being adopted by the healthcare industry more and more from improving diabetes outcomes to reducing unnecessary thyroid surgeries. As these technologies improve, clinicians will soon have yet another ally to individualize patient care. Artificial intelligence. Machine learning. Those very phrases stir up...
Share

Prenatal Precautions: Thyroid Function in Pregnancy

Thyroid dysfunction is fairly common among pregnant women and can often result in additional obstetric complications. A new study published in The Journal of Clinical Endocrinology & Metabolism shows that thyroid screening — despite some controversy as to its usefulness — could help identify women who might benefit from additional prenatal care. Pregnancy places quite a...
Share

Most Frequent Pathogenic Mutation in RET Carries Very Low Lifetime Risk of Medullary Thyroid Cancer

The most frequent pathogenic mutation in the rearranged during transfection (RET) mutation — p.Val804Met – carries with it a very low lifetime risk of medullary thyroid cancer (MTC), which could mean the American Thyroid Association’s (ATA) recommendation of prophylactic thyroidectomy as standard for all RET mutation carriers is inappropriate, according to a study recently published...

Endocrine News provides the latest news and research articles on thyroid conditions and treatment. For more info read this month’s issue of Endocrine News.